Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.

Literature DB >> 15014320

Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.

H Cody Meissner, Margaret B Rennels, Larry K Pickering, Caroline B Hall.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2004 PMID： 15014320 DOI： 10.1097/01.inf.0000121203.33560.f9

Source DB: PubMed Journal: Pediatr Infect Dis J ISSN： 0891-3668 Impact factor: 2.129

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

Review 1. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

Authors: Kerry M Empey; R Stokes Peebles; Jay K Kolls
Journal: Clin Infect Dis Date: 2010-05-01 Impact factor: 9.079

2. Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection.

Authors: Mari Numata; Yoji Nagashima; Martin L Moore; Karin Z Berry; Mallory Chan; Pitchaimani Kandasamy; R Stokes Peebles; Robert C Murphy; Dennis R Voelker
Journal: J Lipid Res Date: 2013-06-06 Impact factor: 5.922

3. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.

Authors: Kelly Huang; Len Incognito; Xing Cheng; Nancy D Ulbrandt; Herren Wu
Journal: J Virol Date: 2010-06-02 Impact factor: 5.103

4. The burden of respiratory syncytial virus infection in young children.

Authors: Caroline Breese Hall; Geoffrey A Weinberg; Marika K Iwane; Aaron K Blumkin; Kathryn M Edwards; Mary A Staat; Peggy Auinger; Marie R Griffin; Katherine A Poehling; Dean Erdman; Carlos G Grijalva; Yuwei Zhu; Peter Szilagyi
Journal: N Engl J Med Date: 2009-02-05 Impact factor: 91.245

5. Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide.

Authors: Manuela Donalisio; Marco Rusnati; Valeria Cagno; Andrea Civra; Antonella Bugatti; Andrea Giuliani; Giovanna Pirri; Marco Volante; Mauro Papotti; Santo Landolfo; David Lembo
Journal: Antimicrob Agents Chemother Date: 2012-07-30 Impact factor: 5.191

Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.

Review 1. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

2. Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection.

3. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.

4. The burden of respiratory syncytial virus infection in young children.

5. Inhibition of human respiratory syncytial virus infectivity by a dendrimeric heparan sulfate-binding peptide.

6. High rate of viral identification and coinfections in infants with acute bronchiolitis.

Review 7. The Multifaceted Roles of Autophagy in Infectious, Obstructive, and Malignant Airway Diseases.

Review 8. The infectious march: the complex interaction between microbes and the immune system in asthma.

9. RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function.